Swedish Orphan Biovitrum AB/Skr SOBI
1D1W1MYTD1Y5YMAX
Capital at risk
About Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB is a biotechnology company primarily focused on developing and commercializing specialty pharmaceuticals for rare diseases. The company is active in therapeutics for hematology, immunology, and genetic and metabolic disorders. Swedish Orphan Biovitrum was founded in 2001 and is headquartered in Stockholm, Sweden. The company operates globally, reaching markets in Europe, North America, and other regions. A key aspect of its strategic positioning is its commitment to addressing unmet medical needs in rare diseases, which often provides a unique market niche. The company invests significantly in research and development to fuel growth and innovation in its therapeutic areas.
- Ticker
- Skr SOBI
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 2,119
- Headquarters
- Stockholm, Sweden
- Website
- www.sobi.com
SOBI Metrics
BasicAdvanced
kr 153B
110.93
kr 3.96
0.29
-
Price and volume
Market cap
kr 153B
Beta
0.29
52-week high
kr 487.00
52-week low
kr 262.80
Average daily volume
307K
Financial strength
Current ratio
0.875
Quick ratio
0.551
Long term debt to equity
20.663
Total debt to equity
41.607
Interest coverage (TTM)
13.34%
Profitability
EBITDA (TTM)
12,414
Gross margin (TTM)
78.49%
Net profit margin (TTM)
4.51%
Operating margin (TTM)
30.53%
Effective tax rate (TTM)
-11.71%
Revenue per employee (TTM)
kr 14,450,000
Management effectiveness
Return on assets (TTM)
7.71%
Return on equity (TTM)
3.40%
Valuation
Price to earnings (TTM)
110.93
Price to revenue (TTM)
4.951
Price to book
3.6
Price to tangible book (TTM)
-8
Price to free cash flow (TTM)
33.356
Free cash flow yield (TTM)
3.00%
Free cash flow per share (TTM)
13.155
Growth
Revenue change (TTM)
13.54%
Earnings per share change (TTM)
-68.61%
3-year revenue growth (CAGR)
15.07%
10-year revenue growth (CAGR)
21.58%
3-year earnings per share growth (CAGR)
-27.09%
10-year earnings per share growth (CAGR)
6.15%
Bulls say / Bears say
Q2 2026 revenue of SEK 7 842 million (27% YoY) beat IBES estimates of SEK 7 289 million, driven by strong sales of Altuvoct, Doptelet, and Gamifant. (Reuters)
The pivotal Phase 3 REDUCE 2 study for pozdeutinurad met its primary endpoint with both doses achieving significant serum uric acid reduction at month 6, strengthening Sobi’s gout pipeline. (Reuters)
Following robust H1 performance, Sobi raised its full-year 2026 revenue growth outlook to mid-to-high-teens at constant FX and upgraded its adjusted EBITA margin guidance to the mid-to-high-30s percent range. (Reuters)
The FDA issued a Complete Response Letter for NASP, delaying approval of Sobi’s uncontrolled gout therapy due to deficiencies in manufacturing controls at contract facilities, pushing back market entry beyond initial expectations. (Reuters)
Sobi’s potential uncontrolled gout franchise faces entrenched competition from Amgen’s Krystexxa, the only FDA-approved therapy in this segment, risking market share loss during Sobi’s prolonged resubmission process. (Reuters)
Net debt rose to just over SEK 16 billion following funding of the Arthrosi acquisition, resulting in a net debt/EBITA ratio of approximately 1.3×, which may constrain Sobi’s financial flexibility and increase interest burden. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
Upcoming events
No upcoming events
Funds containing SOBI
AllEURGBPUSD
Fund name | Fund size | Skr SOBI weighting |
|---|---|---|
iShares STOXX Europe Mid 200€EXSD | €610M | 0.58% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 0.58% |
iShares Ageing Population€AGED | €822M | 0.49% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 0.45% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 0.45% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.